Cancer Detection

Our mission at Elypta is to prevent cancer mortality through earlier detection and closer monitoring  


Liquid biopsies

meet metabolism

We measure metabolic biomarkers in blood and urine and use machine learning to detect signatures of cancer

Connected man original.jpg

Why a liquid biopsy based on metabolism?

Medical imaging and tissue biopsies - the current gold standard in most indications - are ill-suited for close tracking of disease as they are associated with risks, high costs and inconvenience for patients.

Molecular approaches could provide a solution. However, single molecule biomarkers are not sensitive or specific enough for the vast majority of cancers.


Elypta’s approach is to measure a system of metabolic biomarkers - a profile of metabolites found to reflect an important process in cancer - in both blood and urine.

Our learning algorithms then pin down the patterns specific to various forms of cancer using clinical data.

Connected dots original.jpg


Elypta is developing a liquid biopsy platform based on a scalable laboratory assay and artificial intelligence algorithms trained by our clinical database.

Elypta proudly sponsors the clinical trial series AURORAX to investigate applications in our lead indication renal cell carcinoma from surveillance of recurrence to monitoring treatment response. We also explore several other indications to understand the full potential for Elypta’s platform. 


Help us advance
cancer detection



We welcome partnerships with academia to explore clinical applications across indications as well as industry for development of companion diagnostics


Join us

Elypta is looking to expand the team on all levels, feel free to contact us



We welcome interest from investors and are happy to provide more information on Elypta’s plans for development and commercialisation on request